Healthcare Providers Underestimate Patients’ Glucocorticoid Use in Crohn’s Disease
Subrata Ghosh(University College Cork), Stefan Schreiber(Christian-Albrechts-Universität zu Kiel), Brian Bressler(University of British Columbia), Martha Skup(AbbVie (United States)), Song Wang(Fujian Agriculture and Forestry University), Jingdong Chao(AbbVie (United States)), Remo Panaccione(University of Calgary), Roopal Thakkar(Abbott (United Kingdom)), Jill Petkau(Alberta Health Services)
Cited by 8
Related Papers
Vedolizumab as Induction and Maintenance Therapy for Crohn's Disease
|New England Journal of Medicine|2013|2.7k
Genome-wide association study reveals genetic risk underlying Parkinson's disease
|Nature Genetics|2009|2k
Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): Determining Therapeutic Goals for Treat-to-Target
|The American Journal of Gastroenterology|2015|1.8k
Ustekinumab as Induction and Maintenance Therapy for Crohn’s Disease
|New England Journal of Medicine|2016|1.8k